clinical trial · NCT06057454
R-5280 in Newly Diagnosed Patients With Type 1 Diabetes
Type 1 DiabetesType 1 Diabetes (Juvenile Onset)Diabetes Mellitus, Type 1R-5280Placebo
brief summary
Evaluating the adverse events and tolerance of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
started
Dec 5, 2023
primary completion
Nov 5, 2025
completion
Nov 5, 2025
last updated
Nov 10, 2025
detailed description
Double blinded, placebo controlled, Phase 1B study assessing the safety and efficacy of 12 weeks daily administrations of R-5280 in newly diagnosed Type 1 Diabetes adolescents
official title
Evaluating the Safety and Tolerability of R-5280 in Mitigating Type 1 Diabetes in Newly Diagnosed Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol